Pre-made Coltuximab benchmark antibody ( Whole mAb ADC, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Coltuximab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-116-1mg	1mg	Inquiry
GMP-Bios-ab-116-10mg	10mg	Inquiry
GMP-Bios-ab-116-100mg	100mg	Inquiry
GMP-Bios-ab-116-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Coltuximab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody
INN Name	Coltuximab
Target	CD19
Format	Whole mAb ADC
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	6ani:HL:IM
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	ImmunoGen
Conditions Approved	na
Conditions Active	Diffuse large B cell lymphoma
Conditions Discontinued	Precursor cell lymphoblastic leukaemia-lymphoma
Development Tech	na